Activating HER2 point mutations (e.g., L755S, T862A, and T798M), and the truncated p95HER2 mutation, has been associated with resistance to HER2 therapies in breast cancer patients [73,74,75]. This evidence concerns the gene ERBB2 and breast cancer.